The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Bronson Bets on Employer Health Plan as Others Exit

Kalamazoo, Michigan-based Bronson Healthcare is launching Bronson Preferred Health Plan, a new coverage option aimed at employers in southwest Michigan, according to Becker's Hospital Review. The plan runs through a partnership with Key Benefit Administrators, a third-party administrator that handles the claims and benefits machinery, letting Bronson focus on steering patients to its own care network.

The timing is notable. Bronson is ramping up its employer coverage push at the same moment several health systems are backing away from running their own health plans, which have proven hard to operate profitably and capital-intensive to scale. Bronson spent recent years weighing different models before committing, with leaders urging systems to "be honest with yourself" about whether they have the appetite and expertise to compete with established insurers.

Partnering with a TPA rather than building a full insurance arm lowers the risk. Bronson keeps the local provider relationships and premium dollars tied to its system while outsourcing the administrative burden that has sunk other provider-led plans.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.